Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera
about
JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk?Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosisMechanisms of thrombogenesis in polycythemia veraImpaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy.Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohortLysyl oxidase is associated with increased thrombosis and platelet reactivity.Disordered haematopoiesis and athero-thrombosis.Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia.Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.The association between gene polymorphisms and leukocytosis with thrombotic complications in patients with essential thrombocythemia and polycythemia veraRole of platelet counts in the management of essential thrombocythemia: experience with anagrelide.Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.Are MPNs vascular diseases?Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.Advances and challenges in the management of essential thrombocythemia.Platelet expression of PKCepsilon oncoprotein in myelofibrosis is associated with disease severity and thrombotic risk.Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.Biomarkers for Prediction of Central Venous Catheter Related-Thrombosis in Patients With Hematological Malignancies.Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.Platelet haemostatic properties in β-thalassaemia: the effect of blood transfusion.sEPCR Levels in Chronic Myeloproliferative Diseases and Their Association with Thromboembolic Events: A Case-Control Study.Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasmImatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation.Blood cell activation in myeloproliferative neoplasms.Splanchnic vein thrombosis, the onset manifestation in JAK positive Chronic Myeloproliferative Disorders Neoplasms.The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms.Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status.Elevated plasma concentration of NO and cGMP may be responsible for the decreased platelet aggregation and platelet leukocyte conjugation in platelets hypo-responsive to catecholamines.Coagulation deficiencies: a look to the future.JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.Thrombin generation and procoagulant phospholipids in patients with essential thrombocythemia and reactive thrombocytosis.Global coagulation in myeloproliferative neoplasms.A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective.Comparison of JAK2(V617F) -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology.
P2860
Q30572002-24702D34-2C26-4231-873D-21FBCBDAB824Q33359341-F66403F1-2909-442C-A977-26BDB5C6891FQ33398180-D223EF33-48E1-447F-9108-1224B522C915Q33711653-D47EABC6-EF10-4177-A28E-EB4675B45C5CQ35738656-521EB808-C013-43FB-91D3-1A829AACA2C0Q36303858-3D03A2D7-E713-4C1C-97FE-DA940D37609DQ36316145-36B1FBFE-9A92-41CC-AF8E-3D4BE44CC6E7Q36700494-1A71BC1A-04E7-4A1F-A6D8-99EB82A544E6Q36773876-3FA8B18B-E918-4545-B0AD-0862F16FBDB2Q37246729-3E3AB2F8-CBAF-409E-9592-717C789CE121Q37275858-8BD1E581-C633-4177-BA3E-EB81DFC9E4E1Q37638779-C72DB1A4-2FFA-47BC-815C-C9A130385458Q37703132-CF4B98A2-5A8F-4A72-9176-638785C79CD4Q37810089-C4E7740B-3FF2-47AE-93B9-8766231F249EQ37973346-A96806E1-19C2-45E2-ACCB-F18D5C46F78BQ38137750-7B450A88-1114-4F7E-92C1-C1795EFDFF77Q38187674-99E5A006-0188-43B5-AE63-F5586A3C58B6Q38542093-D102422F-CCB0-4D58-AC51-31180962083BQ38652524-1719F390-7B07-4A7B-8046-99EE04F78255Q38725723-896CDB45-339B-4C1B-964D-C54EA1554570Q39016660-AD17BA21-CAA3-4FF4-B6C9-25388550C6D0Q39041471-0D68E8A6-987D-4236-8BE1-FEBE3E2E3C90Q39321106-31BFC980-B77C-4178-A121-E1D0AE72A491Q39869975-BED050EB-B1C0-4E4B-B547-35D68B278FD1Q41547084-7EE7EB0C-E951-4EAA-B533-D735EDDC0CB7Q42107801-9FCAA32E-2995-4512-9186-C4A420E3D4E7Q42189605-8928EA10-0B13-4E92-8681-92BF65A2B3DAQ42201127-75E832AB-7F63-4404-845E-02A3176DAD41Q42348456-4F2E9A09-4506-4D58-A7FE-814F04087E3DQ42604571-07EEC084-87AF-49CB-8F26-453952F4D0BEQ42684523-CE7C2A3D-8B47-42A0-9417-A09695A56227Q42943367-A62296FF-89A5-489A-A5E7-F1ADA87CA0A1Q42976187-FC6B35B2-8EEE-47BF-A95B-9CD81F09BDC2Q43252745-2041FF49-EB92-4677-AB3A-3D4AB0457A74Q43517013-4750F5C7-E1FA-453F-B3C5-A5076E1DB469Q44985081-3C3DBDDF-EF65-4EE2-9088-B36A37D8613AQ45710734-04397690-8EF9-46AC-85BC-8931AE13A03AQ45723065-5C4832E3-47D3-4176-8199-EB013802CB6AQ47813570-9623BADF-ACD3-48A0-832D-546868A73888Q48138032-9C378BBD-9945-4229-A60C-5B91E61899F5
P2860
Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Leukocyte-platelet interaction ...... cythemia and polycythemia vera
@ast
Leukocyte-platelet interaction ...... cythemia and polycythemia vera
@en
Leukocyte-platelet interaction ...... cythemia and polycythemia vera
@nl
type
label
Leukocyte-platelet interaction ...... cythemia and polycythemia vera
@ast
Leukocyte-platelet interaction ...... cythemia and polycythemia vera
@en
Leukocyte-platelet interaction ...... cythemia and polycythemia vera
@nl
prefLabel
Leukocyte-platelet interaction ...... cythemia and polycythemia vera
@ast
Leukocyte-platelet interaction ...... cythemia and polycythemia vera
@en
Leukocyte-platelet interaction ...... cythemia and polycythemia vera
@nl
P2093
P1476
Leukocyte-platelet interaction ...... cythemia and polycythemia vera
@en
P2093
Alfonso Vignoli
Anna Falanga
Donatella Balducci
Marina Marchetti
Tiziano Barbui
P304
P356
10.1016/J.EXPHEM.2005.01.015
P407
P577
2005-05-01T00:00:00Z